Navigation Links
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Date:11/2/2007

ment for hepatitis C patients with unmet needs, including patients co-infected with HIV and HCV, African Americans, patients with cirrhosis, and patients who have failed to respond to previous therapy.

Important Safety Information about PEGASYS

PEGASYS, alone or in combination with COPEGUS, is indicated for the treatment of adults with chronic hepatitis C virus infection who have compensated liver disease and have not been previously treated with interferon alpha. Patients in whom efficacy was demonstrated included patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A).

Alpha interferons, including PEGASYS(R) (Peginterferon alfa-2a), may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Therapy should be withdrawn in patients with persistently severe or worsening signs or symptoms of these conditions. In many, but not all cases, these disorders resolve after stopping PEGASYS therapy (see CONTRAINDICATIONS, WARNINGS, PRECAUTIONS and ADVERSE REACTIONS in complete product information).

Use with Ribavirin. Ribavirin, including COPEGUS(R), may cause birth defects and/or death of the fetus. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients. Ribavirin causes hemolytic anemia. The anemia associated with ribavirin therapy may result in a worsening of cardiac disease. Ribavirin is genotoxic and mutagenic and should be considered a potential carcinogen (see CONTRAINDICATIONS, WARNINGS, PRECAUTIONS and ADVERSE REACTIONS in complete product information).

PEGASYS is contraindicated in patients with hypersensitivity to PEGASYS or any of its components, autoimmune hepatitis, and hepatic decompensation (Child-Pugh score greater than 6; class B and C) in cirrhotic CHC monoinfected patients before or during tre
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... and PITTSBURGH , July 27, 2015 /PRNewswire/ ... will hold its extraordinary general meeting of shareholders in connection ... PRGO ; TASE) at the Okura Hotel Amsterdam on Friday, ... Among other agenda items at the extraordinary ... approval, under article 2:107a of the Dutch Civil Code, of ...
(Date:7/27/2015)... , July 20, 2015 ... announced the addition of the "Cardiometabolic Drug ... Afrezza,s discounted pricing is in line with ... critical to the product,s commercial appeal. However, contraindications, ... Afrezza from gaining a sizeable share of the ...
(Date:7/27/2015)...  Linear accelerators used to treat patients with ... adequate space for the equipment itself, but also ... the size and complexity of the technology, full ... of a new vault constitutes a formidable undertaking ... patient treatment: with potential negative long-term effects for ...
Breaking Medicine Technology:Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 2Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 3Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 4Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 5Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 6Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 7Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 8Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 9Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 10Cardiometabolic Drug News Issue - Afrezza Aggressive Pricing Strategy View Playing Out 2Cardiometabolic Drug News Issue - Afrezza Aggressive Pricing Strategy View Playing Out 3Accelerating the Design Process for Cancer Treatment Centers 2Accelerating the Design Process for Cancer Treatment Centers 3
... 23, 2011 PharmacoFore, Inc., a privately held ... announced positive results from a Phase I human ... Molecular Delivery™ (Bio-MD™) product candidate, PF329.  Greg Sturmer, ... 2011 BIO Business Forum during the annual BIO ...
... Luminex Corporation (NASDAQ: LMNX ) has ... Most Innovative Company of the Year (for companies with ... Year for the MAGPIX System.  A record number of ... organizations from virtually all company sizes and industries.  In ...
Cached Medicine Technology:PharmacoFore, Inc. Announces Positive Results from a Phase I Clinical Study of Its Hydromorphone Bio-Activated Molecular Delivery™ System, and Upcoming Presentation at the 2011 BIO Business Forum During the Annual BIO International Convention in Was 2PharmacoFore, Inc. Announces Positive Results from a Phase I Clinical Study of Its Hydromorphone Bio-Activated Molecular Delivery™ System, and Upcoming Presentation at the 2011 BIO Business Forum During the Annual BIO International Convention in Was 3PharmacoFore, Inc. Announces Positive Results from a Phase I Clinical Study of Its Hydromorphone Bio-Activated Molecular Delivery™ System, and Upcoming Presentation at the 2011 BIO Business Forum During the Annual BIO International Convention in Was 4Luminex Corporation Named Most Innovative Company of the Year and Receives Business Innovation of the Year Award for MAGPIX® System 2Luminex Corporation Named Most Innovative Company of the Year and Receives Business Innovation of the Year Award for MAGPIX® System 3
(Date:7/27/2015)... ... July 28, 2015 , ... ... as the sports medicine provider for the entire school district including Anderson County ... ACHS Athletic Director Rick Sallee, “Student safety and well-being are a top priority ...
(Date:7/27/2015)... ... July 28, 2015 , ... The National Association of Professional ... VIP Woman of the Year Circle. She is recognized with this prestigious distinction for ... boasting more than 700,000 members and over 200 operating Local Chapters. , “I’m pleased ...
(Date:7/27/2015)... ... July 27, 2015 , ... Interactive health education is ... this year Wound Care Advantage beta launched Luvo University, an online ... Customized learning paths allow for clinicians, physicians, hyperbaric technicians and non-clinical staff ...
(Date:7/27/2015)... (PRWEB) , ... July 27, 2015 , ... ... transformed the science of the little-known and incurable disease, facioscapulohumeral muscular dystrophy (FSHD), ... American Academy of Neurology (AAN). The FSHD care guideline is published today. ...
(Date:7/27/2015)... ... ... Looking to brush up on all the things you should be doing ... enhanced its Dental webpage with new materials, including user-friendly, educational videos, to help members ... to offering our 3.8 million members tools and resources to help them keep a ...
Breaking Medicine News(10 mins):Health News:KORT Physical Therapy Named Sports Medicine Provider for Anderson County School System 2Health News:KORT Physical Therapy Named Sports Medicine Provider for Anderson County School System 3Health News:NAPW Inducts Joanne Saniewski, Principal of the Frontier School District's Big Tree Elementary, Into its VIP Woman of the Year Circle 2Health News:Wound Care Advantage Launches Luvo University An Online Hub For Wound Care Education and Training 2Health News:Wound Care Advantage Launches Luvo University An Online Hub For Wound Care Education and Training 3Health News:First-Ever FSHD Evidence-based Care Guideline Published by the American Academy of Neurology 2Health News:Thinking about a Dental Check-up? Check out Horizon Blue Cross Blue Shield of New Jersey’s Enhanced Website for a Dental Download of Helpful Information 2
... Leverages Personal Health Care Utilization and Employee Data to ... WHO: Daryl Ashley, senior vice president and general ... Benefits Administration for Workscape, a leading ... Will be a featured presenter in the "Getting Personal -- ...
... and anchor ... depth, ... SN) Endoscopy Division today announced the launch of the,BIORAPTOR 2.3 PK Suture ... is featured at Smith & Nephew Endoscopy,s booth,at the American Academy of ...
... Care,Spending May More Than Double as Hospital Capacity Declines And Baby Boomer ... ... of over 70,million aging baby boomers could overwhelm the U.S. health care ... the,Boom Bust Health Care?," by management consulting firm Tefen USA., A ...
... to Invest in Your Teeth, VOORHEES, N.J., March ... should be similar for 2007. Together with the,government,s economic ... in the pockets of most taxpayers this Spring, it,s ... vacations., But rather than getting away for a ...
... Associate at Kendle ... International, Inc., Joins Catalyst, CORAL GABLES, Fla., March 5 ... the,appointment of Patrick Kenny as Director - Corporate Clinical Compliance.,In ... and GCP compliance of the CROs, clinical contractors and,clinical trial ...
... 1999,OurHealthNetwork.com ( http://www.OurHealthNetwork.com ) has been the,Internet,s leading ... board- certified podiatrists now introduces an exclusive line ... orthotics that not only,provide relief to those who ... their,lifestyles and shoe styles. Now for the first ...
Cached Medicine News:Health News:Upcoming Business Health Agenda 2008 Features Workscape Executive 2Health News:Smith & Nephew Endoscopy's BIORAPTOR(TM) 2.3 PK Suture Anchor Provides Secure Repair for Shoulder, Hip Instability 2Health News:Smith & Nephew Endoscopy's BIORAPTOR(TM) 2.3 PK Suture Anchor Provides Secure Repair for Shoulder, Hip Instability 3Health News:Smith & Nephew Endoscopy's BIORAPTOR(TM) 2.3 PK Suture Anchor Provides Secure Repair for Shoulder, Hip Instability 4Health News:New Study: Aging Baby Boomers Could Overwhelm U.S. Health Care System by 2017, Unless Decisive Action Is Taken 2Health News:New Study: Aging Baby Boomers Could Overwhelm U.S. Health Care System by 2017, Unless Decisive Action Is Taken 3Health News:New Study: Aging Baby Boomers Could Overwhelm U.S. Health Care System by 2017, Unless Decisive Action Is Taken 4Health News:Smile When You Get that Refund 2Health News:Catalyst Pharmaceutical Partners, Inc. Names Director - Corporate Clinical Compliance 2Health News:Catalyst Pharmaceutical Partners, Inc. Names Director - Corporate Clinical Compliance 3Health News:Catalyst Pharmaceutical Partners, Inc. Names Director - Corporate Clinical Compliance 4Health News:Unique Line of Custom-Made Orthotics for Sandals and Clogs Cater to Style-Minded Foot Pain Sufferers 2
Well established test for children but suitable for disabled people, those with learning difficulties or patients who do not share a common language with the examiner....
The FLEXI-CUT Directional Debulking System is Abbott Vascular's latest atherectomy catheter designed to enhance performance and ease-of-use....
This test displays normal protan, deutan and tritan colors, differentiation is stronger in the red/green., ,Significant tritan defects may be detected if used in conjunction with the Ishihara. Th...
The New Vantage Plus. The PLUS gives you: ,P Premium intelligent optics ,L Lighter weight and brighter images ,U Unique wireless patented technology ,S Smaller and more compact size ...
Medicine Products: